About Us

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities.

Our team was built with deep expertise in genetic medicine development and manufacturing, allowing us to efficiently advance our programs from preclinical to clinical development. Our core capabilities in viral vector design and optimization together with our in-house manufacturing ecosystem provide us a differentiated advantage to developing genetic medicines.

Additionally, we are developing a proprietary technology to enable innovative gene therapy treatments whose expression can be switched on and off in a dose-dependent manner with an orally administered small molecule. We believe temporal control of genetic medicine products has the potential to transform the genetic medicine landscape.

Lastly, our end-to-end manufacturing ecosystem includes an industry-leading manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities, as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply.